NEW YORK, Sept. 26, 2018 (GLOBE NEWSWIRE) -- Levi & Korsinsky announces it has commenced an investigation of TG Therapeutics, Inc. (“TG Therapeutics” or “the Company”) (NASDAQCM: TGTX) concerning possible violations of federal securities laws.

On September 25, 2018, TG Therapeutics issued a press release announcing “that the independent Data Safety Monitoring Board (DSMB) for the UNITY-CLL Phase 3 trial met to review ongoing data from the study and advised the Company that the interim analysis of Overall Response Rate (ORR) could not be conducted at this time as the data were not sufficiently mature to conduct the analysis.” Following this news, shares of TG Therapeutics fell more than 44% to close at $5.15 per share on September 25, 2018. To obtain additional information, go to:

https://www.zlk.com/pslra-1/tg-therapeutics-inc-loss-form

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:   
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor

New York, NY 10006
Tel: (212) 363-7500
Toll Free:  (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.